ViiV Healthcare's Dovato Combo Regime Shows Encouraging Long Term Data In HIV Patients

ViiV Healthcare, a joint venture between GlaxoSmithKline plc GSK, Pfizer Inc PFE, and Shionogi, presented three-year results from the TANGO study at IDWeek 2021.
Phase 3 TANGO study assessed the antiviral efficacy and safety of switching to Dovato, a 2-drug regimen of dolutegravir/lamivudine in HIV-infected adults who are virologically suppressed stable on a tenofovir alafenamide fumarate (TAF)-based regimen.
Related Link: ViiV In-Licenses Third-Gen HIV Targeting Compound From Shionogi.
The findings demonstrated the non-inferiority of Dovato compared to the continuation of TAF-based regimens in the Intention to Treat-Exposed (ITT-E) population.
In the ITT-E population, both treatment arms showed a high proportion of participants with plasma HIV-1 RNA over 50 c/mL, with Dovato demonstrating non-inferior virologic suppression to the TAF-based regimen (85.9% vs. 81.7% respectively).
Overall adverse event (AE) rates were similar between the study arms, with more drug-related AEs with Dovato versus the TAF-based regimens arm (6% vs. 4%).
Also Read: GSK, Pfizer Backed Long-Acting HIV Med Under FDA Priority Review As Preventative Option
Price Action: PFE stock is up 0.28% at $43.16, and GSK stock is up 0.21% at $38.13 during the premarket session on the last check Wednesday.